about
sameAs
On the Quest of Cellular Functions of PEA-15 and the Therapeutic OpportunitiesPhase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast CancerCooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.Screening for novel protein targets of indomethacin in HCT116 human colon cancer cells using proteomicsMaintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phaMulti-gram scale synthesis of FR180204.A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasOverexpression of tumor necrosis factor receptor-associated protein 1 (TRAP1), leads to mitochondrial aberrations in mouse fibroblast NIH/3T3 cells.Inhibition of mesothelin as a novel strategy for targeting cancer cells.Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinomaIdentification of extracellular signal-regulated kinase 1 (ERK1) direct substrates using stable isotope labeled kinase assay-linked phosphoproteomics.Identification of differentially expressed genes in papillary thyroid cancers.Altered tumor biology and tumorigenesis in irradiated and chemical carcinogen-treated single and combined connexin32/p27Kip1-deficient mice.The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.Pharmacogenetic candidate genes for melanoma.A new look at an old problem: the survival and organ-specific growth of metastases.Therapeutic modulation of signal transduction pathways.Targeting the ubiquitin-proteasome pathway in breast cancer therapy.Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity.Recent advances in the therapy of renal cancer.Up-regulation of REG3A in colorectal cancer cells confers proliferation and correlates with colorectal cancer risk.Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report.Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastasesDisruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis.Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.The role of hepatitis B virus X protein is related to its differential intracellular localization.Opioid receptor trafficking and signaling: what happens after opioid receptor activation?Genomic medicine for cancer diagnosis.RKIP and 14-3-3ε exert an opposite effect on human gastric cancer cells SGC7901 by regulating the ERK/MAPK pathway differently.MEK inhibitors in oncology: a patent review (2015-Present).RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo.Models of melanoma metastasis: using a transient siRNA-based protein inhibition strategy in mice to validate the functional relevance of pharmacological agents.Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.Mitogen-activated protein kinase signalling pathways triggered by the hepatitis C virus envelope protein E2: implications for the prevention of infection.Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line.Drug-likeness of Phytic Acid and Its Analogues.
P2860
Q26799216-ADB2E8D5-91B7-4902-9291-191B933CC2EFQ28555102-D2B25950-BF39-4973-A676-189206C7526EQ30422676-63B7B6E3-D65C-4087-B705-C648E873A963Q31142615-59B7F7F9-D260-4425-8D76-D809AED0FFEDQ33692392-4A4B178A-3AAA-47E4-ADAF-054276820209Q33822978-CE30E2CF-31BF-4E22-8FCD-4F5FCFE09DDEQ34063343-B291C545-4A4F-4D45-B7C5-7BBAC97BD82BQ34179900-4EA6C8D8-CD5D-4DB5-B041-FFBD53BDEED0Q34224746-5DA26F26-3573-49D1-8D61-14C2BCD3A132Q34318833-F0B1C331-795B-45F6-A349-B0B01FA91CE1Q34468439-3B313DC0-9294-432C-93B6-DF1230FC4003Q34956249-7907178E-D6E5-4CD1-AA11-8C61A7662F09Q35039199-27781F5A-EB52-40B0-8E9C-6301DDE451C3Q35081944-A02D86EA-A436-45F7-90E9-B6E372A82747Q35574952-F398F101-D041-4E23-B2C7-1DB7A47183BDQ35634251-65087C11-718D-411E-9B6A-1E75E33391C9Q35787657-298431B4-B650-4DE1-94D6-D8D28599A5F2Q36429691-683BF0F0-8F97-4907-9B93-C0188201D070Q36613302-05438864-872E-476F-BEFA-F14C4F0810EAQ36717355-5DC48DCE-3238-420A-8C85-22594F2FD845Q36782310-56A3B6E1-DED8-4743-A036-3B09B0BC94B3Q36822926-2C23E692-F4C4-423C-BE52-D227FB0597CFQ36992993-48B9533F-8A54-418B-81B4-1C97B0E64F74Q37071204-565999C9-94C0-4F07-B53D-AB8DEF4AC527Q37344465-F264AD2F-4939-4021-AA86-9BCCC6DCDC21Q37360151-56FCBA23-AD83-4FFB-9536-8E95F262EF6EQ37421620-A78C73DA-1086-4A93-B896-71F6E27D03EAQ37574057-A6B63B66-9A3B-4EBA-8665-1EE5B1239847Q37828640-C4457833-7C66-44FF-966C-E49276C90C3FQ37892740-AD8E8293-CC5C-484D-92EB-2AD7E2F15310Q37938862-0CC62756-287F-4967-BB8A-417E20C05226Q38262839-C54DB326-E6C2-49D2-B655-1A78104016C3Q39296228-58A7FCE0-C8BF-4159-A57F-505FDA4CA09BQ39359514-FC1D50DA-072A-45CF-96F0-65FEBE211028Q39975996-5177E4B6-FCA2-49FA-8E0A-22AFF1A5FD5EQ40087403-DD8E5DAB-22E7-4138-8CAC-FC668963FEF8Q40092301-4740E316-1F13-4407-BF9F-320A943CEBE5Q40106501-1FC38A1C-A860-4083-87B9-74F480BA8858Q40495935-2DC9D69B-C7B4-4231-AB3E-EF521DBE566DQ41976059-32F277BC-EDC3-4C10-B34A-A3BDDBF517C5
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The Ras-Raf-MEK-ERK pathway in the treatment of cancer
@ast
The Ras-Raf-MEK-ERK pathway in the treatment of cancer
@en
The Ras-Raf-MEK-ERK pathway in the treatment of cancer
@nl
type
label
The Ras-Raf-MEK-ERK pathway in the treatment of cancer
@ast
The Ras-Raf-MEK-ERK pathway in the treatment of cancer
@en
The Ras-Raf-MEK-ERK pathway in the treatment of cancer
@nl
prefLabel
The Ras-Raf-MEK-ERK pathway in the treatment of cancer
@ast
The Ras-Raf-MEK-ERK pathway in the treatment of cancer
@en
The Ras-Raf-MEK-ERK pathway in the treatment of cancer
@nl
P2093
P356
P1433
P1476
The Ras-Raf-MEK-ERK pathway in the treatment of cancer
@en
P2093
D Strumberg
M E Scheulen
R A Hilger
P356
10.1159/000068621
P407
P577
2002-12-01T00:00:00Z